Renalytix Beheer

Beheer criteriumcontroles 2/4

De CEO Renalytix is James McCullough, benoemd in Mar2018, heeft een ambtstermijn van 6.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 780.11K, bestaande uit 65.3% salaris en 34.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde £ 41.15K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 1.3 jaar.

Belangrijke informatie

James McCullough

Algemeen directeur

US$780.1k

Totale compensatie

Percentage CEO-salaris	65.3%
Dienstverband CEO	6.7yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	1.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is James McCullough's beloning veranderd ten opzichte van Renalytix's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	US$780k	US$510k	-US$33m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	n/a	n/a	-US$42m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	US$1m	US$601k	-US$46m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	n/a	n/a	-US$42m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	US$636k	US$601k	-US$45m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	n/a	n/a	-US$44m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	US$1m	US$586k	-US$35m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	n/a	n/a	-US$20m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	US$488k	US$470k	-US$10m
Mar 31 2020	n/a	n/a	US$28m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	US$216k	US$269k	-US$42m

Compensatie versus markt: De totale vergoeding ($USD 780.11K ) James } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 359.47K ).

Compensatie versus inkomsten: De vergoeding van James is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

James McCullough (56 yo)

6.7yrs

Tenure

US$780,110

Compensatie

Mr. James R. McCullough served as Independent Non-Executive Director of LungLife AI, Inc. from July 08, 2021 to October 24, 2024. Mr. McCullough is CEO of Renalytix Plc.and served as Chairman Mr. McCulloug...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James McCullough	CEO & Director	6.7yrs	US$780.11k	0.18% £ 41.2k
Fergus Fleming	CTO & Executive Director	6.7yrs	US$425.70k	0.20% £ 44.1k
Michael Donovan	Chief Medical Officer	6.7yrs	US$380.01k	0% £ 0
Julian Baines	Executive Chairman	less than a year	US$14.89k	0.54% £ 121.6k
Howard Doran	President	less than a year	geen gegevens	geen gegevens
Joel Jung	Chief Financial Officer	less than a year	geen gegevens	0.063% £ 14.1k
Salim Hamir	Company Secretary	no data	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RENX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James McCullough	CEO & Director	no data	US$780.11k	0.18% £ 41.2k
Fergus Fleming	CTO & Executive Director	6.7yrs	US$425.70k	0.20% £ 44.1k
Julian Baines	Executive Chairman	less than a year	US$14.89k	0.54% £ 121.6k
Erik Lium	Independent Non-Executive Director	6yrs	geen gegevens	geen gegevens
Christopher Mills	Independent Non-Executive Director	6.7yrs	geen gegevens	0% £ 0
Stephen Brunton	Member of Clinical Advisory Board	1.3yrs	geen gegevens	geen gegevens
Matthew Budoff	Member of Clinical Advisory Board	1.3yrs	geen gegevens	geen gegevens
Ralph Defronzo	Member of Clinical Advisory Board	1.3yrs	geen gegevens	geen gegevens
Barry Freedman	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Joseph Vassalotti	Member of Clinical Advisory Board	5.3yrs	geen gegevens	geen gegevens
Catherine Coste	Independent Non-Executive Director	1.4yrs	US$68.15k	0.085% £ 18.9k
Holly Mattix-Kramer	Member of Clinical Advisory Board	1.3yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RENX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.

Renalytix Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Renalytix Plc, Annual General Meeting, Dec 19, 2024

Renalytix plc Announces Board Changes

Renalytix plc Announces Step Down of Dan Levangie, Non-Executive Director from the Board

Renalytix Plc Announces Chief Financial Officer Changes

Renalytix plc Announces Executive Changes, Effective from April 30, 2024

Renalytix Plc, Annual General Meeting, Apr 22, 2024

Recent updates

Renalytix Plc, Annual General Meeting, Dec 19, 2024

Renalytix Plc Provides Revenue Guidance for Years 2025, 2026 and 2027

Renalytix Plc announced delayed 10-Q filing

Renalytix plc Announces Board Changes

Renalytix plc Announces Step Down of Dan Levangie, Non-Executive Director from the Board

Renalytix Plc(OTCPK:RNLX.Y) dropped from NASDAQ Composite Index

Renalytix Plc has completed a Follow-on Equity Offering in the amount of £11.80454 million.

Nasdaq Grants Listing Extension to Renalytix

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Renalytix Provides Non-Compliance Update

Renalytix Plc Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: US$0.079 loss per share (vs US$0.14 loss in 3Q 2023)

No longer forecast to breakeven

Renalytix Plc Reports Impairment Loss on Property, Equipment and Other Long-Lived Assets for the Third Quarter Ended March 31, 2024

Renalytix Plc to Report Q3, 2024 Results on May 15, 2024

New major risk - Shareholder dilution

Renalytix plc Announces Executive Changes, Effective from April 30, 2024

Renalytix Plc has filed a Follow-on Equity Offering in the amount of $1 million.

Renalytix Plc has filed a Follow-on Equity Offering in the amount of $4 million.

Renalytix Plc, Annual General Meeting, Apr 22, 2024

Renalytix plc's KidneyIntelX Included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease

Renalytix Plc has completed a Follow-on Equity Offering in the amount of £9.360374 million.

Renalytix Plc has filed a Follow-on Equity Offering in the amount of £7.8 million.

Second quarter 2024 earnings released: US$0.087 loss per share (vs US$0.14 loss in 2Q 2023)

Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for Renalytix Plc's Kidneyintelx and Kidneyintelx.Dkd

Renalytix plc Announces Update on Kidneyintelx.Dkd Local Coverage Determination Consideration

Renalytix Receives Non-Compliance Notice From Nasdaq

Renalytix plc Announces Step Down of Chirag Parikh as Independent Non-Executive Director

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

New major risk - Negative shareholders equity

Renalytix Plc to Report Q1, 2024 Results on Nov 14, 2023

Less than half of directors are independent

Renalytix Plc, Annual General Meeting, Dec 15, 2023

Renalytix Plc Announces the Stepped Down of Timothy Scannell as Independent Non-Executive Director

Consensus revenue estimates fall by 26%

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Renalytix Plc to Report Second Half, 2023 Results on Sep 28, 2023

Renalytix plc Announces the Appointment of Howard Doran as Chief Business Officer

Renalytix plc Announces Appointments to Its Clinical Advisory Board

Renalytix Plc Announces Late-Breaking KidneyIntelX Evidence Released at American Diabetes Association Scientific Sessions

Renalytix plc Appoints Catherine Coste to Board of Directors, Non-Executive Chair of the Audit Committee and a Member of the Remuneration Committee

Fda Grants De Novo Marketing Authorization for Kidneyintelx.Dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease of Renalytix plc

Renalytix Plc Announces KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

New major risk - Financial position

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2022)

Consensus revenue estimates decrease by 22%

Renalytix Plc to Report Q3, 2023 Results on Jun 09, 2023

Consensus revenue estimates increase by 14%

Renalytix Plc, Annual General Meeting, Jun 08, 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.18 loss in 2Q 2022)

Consensus revenue estimates fall by 12%

Renalytix plc Announces the Launch of PRIME-CKD

Renalytix plc Announces That Primary Care Use of Kidneyintelx in Early Stage Ckd Improved Clinical Care Delivery and Outcomes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.14 loss in 1Q 2022)

Consensus forecasts updated

Renalytix Plc to Report Q1, 2023 Results on Nov 30, 2022

Consensus forecasts updated

Renalytix Plc, Annual General Meeting, Dec 19, 2022

No longer forecast to breakeven

Renalytix Plc to Report Q4, 2022 Results on Oct 31, 2022

Renalytix plc Announces Ann Berman, Non-Executive Director and Chair of the Audit and Nomination Committees, Resigns as Director

Renalytix Plc Announces Publication of Clinical Utility Study in The AJMC

Analyse CEO-vergoeding

CEO

Tenure

Compensatie